Answers are grounded in this paper and cite their sources.
A platelet lipoxygenase defect with high thromboxane formation was identified in two young men with myocardial infarction, suggesting a potential pro-thrombotic mechanism.
In 2 male patients (35 and 38 years) presenting with myocardial infarction an abnormal conversion of exogenous 14C-arachidonic acid by the patients' platelets, incubated in vitro, was observed. Neither patient's platelets showed evidence of a lipoxygenase pathway. Platelet thromboxane formation from exogenous and endogenous substrate was high, while the platelet aggregation responses were normal. A myeloproliferative syndrome was excluded by bone marrow puncture. Similar defects have only been described so far in patients with myeloproliferative syndrome. This defect may be causative for the onset of clinical thrombotic events. It is speculative whether in vivo therapy with r-IFN alpha 1c might be able to eradicate the pathological platelet clone.
No takes yet. Share an insight, caveat, or question.
Sinzinger et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: